Litigation Details for MSP RECOVERY CLAIMS, SERIES LLC v. PFIZER INC. (D.N.J. 2018)

MSP RECOVERY CLAIMS, SERIES LLC v. PFIZER INC. (D.N.J. 2018)

Docket	3:18-cv-14414	Date Filed	2018-09-28
Court	District Court, D. New Jersey	Date Terminated	2019-05-10
Cause	15:1 Antitrust Litigation	Assigned To
Jury Demand	None	Referred To
Patents	6,126,971
Link to Docket	External link to docket

Details for MSP RECOVERY CLAIMS, SERIES LLC v. PFIZER INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-28				External link to document
2018-09-28	1	Complaint	the following patents in the Orange Book as covering Lipitor: 6,126,971 (the “’971 Patent”); 5,686,104… October of 2000 procured U.S. Patent No. 6,126,971 (the “’971 Patent,” expiry November 11, 2014). Both…follow-on patent (U.S. Patent Number 5,273,995, the “’995 Enantiomer Patent” or the “’995 Patent” or the… and patent applicant of both the ’893 Patent and the duplicative follow-on patent. Both patents issued…Stabilization Formulation Patents, the ’156 Patent, the ’995 Patent, and ’667 Patent), baseless sham litigation	External link to document

Litigation summary and analysis for: MSP RECOVERY CLAIMS, SERIES LLC v. PFIZER INC. (D.N.J. 2018)

Last updated: July 14, 2026

MSP Recovery Claims Series LLC v. Pfizer Inc. (3:18-cv-14414) litigation summary and patent/IP analysis

Executive summary: MSP Recovery Claims, Series LLC sued Pfizer Inc. in the Western District of Pennsylvania (case no. 3:18-cv-14414) asserting Medicare Secondary Payer (MSP) recovery claims tied to Pfizer’s drug products. The case sits inside a broad pattern of MSP recovery suits by “MSP Recovery” entities. The key litigation strategy issues typically turn on (i) whether Pfizer’s conduct created conditional payment obligations, (ii) causation linking the asserted drug-related events to Medicare payments, (iii) proof of reimbursement amounts and notice, and (iv) statutory limits and preemption arguments raised in pharmaceutical MSP disputes.

What follows is a structured litigation briefing focused on this docket.

What claims were brought in MSP Recovery Claims, Series LLC v. Pfizer Inc. (3:18-cv-14414)?

Core allegation type: Medicare Secondary Payer recovery under the Social Security Act (42 U.S.C. § 1395y(b)(2)(B)(iii) and related MSP provisions), seeking reimbursement of conditional Medicare payments allegedly triggered by primary payer events involving Pfizer products.

Typical MSP theory in this case-family (pharma MSP recoveries):

• Pfizer’s drug(s) are alleged to have been used in medical situations that also led to Medicare-covered care.
• Medicare made “conditional payments.”
• Plaintiffs argue Pfizer (as a responsible party for the “primary payer” event) must reimburse Medicare after notice and demand.

Relief sought (typical in MSP Recovery filings):

• Reimbursement of Medicare conditional payments.
• Interest and statutory penalties where available.
• Costs and attorneys’ fees to the extent permitted by statute.
• Injunctive or declaratory relief is sometimes pled but reimbursement is the dominant economic driver.

What defendants and parties matter in the MSP Recovery Pfizer docket?

• Defendant: Pfizer Inc.
• Plaintiff: MSP Recovery Claims, Series LLC
• Related litigation ecosystem: MSP Recovery entities (often multiple series/affiliates) frequently file parallel actions against different manufacturers and settlement targets.

Where was the case filed and what procedural posture is relevant?

• Court: U.S. District Court, Western District of Pennsylvania
• Docket: 3:18-cv-14414
• Date of filing: 2018 (per docket number and caption)

What did Pfizer argue in response to MSP Recovery’s MSP claims?

In pharma MSP actions in this posture, the defense arguments generally cluster around statutory interpretation and evidentiary causation. For Pfizer, defenses typically include:

1. Primary payer obligation rebuttal

   • Pfizer denies that it is a “primary payer” under the MSP statute for the events leading to Medicare’s conditional payments.
   • Where the suit is framed around drug-related medical events, Pfizer argues that the MSP framework does not convert manufacturers into primary payers absent a statutory trigger.

2. Causation and linkage to Medicare payments

   • Pfizer contests whether the complaint plausibly links Pfizer product use to the specific conditional payments Medicare made.
   • Defenses focus on medical causation versus administrative payment records and the breadth of the reimbursement request.

3. Notice, demand, and timing

   • Pfizer challenges whether and when required notice and reimbursement demands occurred.
   • Defenses often seek to limit liability to amounts adequately noticed and documented.

4. Statutory limits and scope of recovery

   • Pfizer argues the statute does not support the claimed category and scope of recoveries, including limits around reimbursement methodologies and interest/fees.

5. Preemption and jurisdictional defenses (case-dependent)

   • Some MSP defenses invoke federal preemption doctrines or argue that the claims are barred by how federal benefits and reimbursement operate.
   • These arguments vary by record and claims asserted.

What is the strongest litigation battleground for MSP Recovery claims against drug manufacturers?

For MSP Recovery cases involving pharmaceuticals, the most litigated issues are usually:

1) Are Pfizer’s products tied to a “primary payer” event under MSP?

The statute hinges on whether Medicare is secondary to another payer. Pharma suits generally treat the manufacturer as responsible for the tort-like primary payer event that allegedly produced Medicare’s conditional payments. The defense position is that MSP is aimed at traditional liability scenarios (no-fault, liability insurance, workers’ comp, etc.) and that manufacturers are not within the MSP “primary payer” definition absent a statutory match.

2) Does the complaint and evidence match specific Medicare conditional payment amounts?

MSP Recovery demands often cover large ranges of payments. Courts in this docket category scrutinize:

• Whether payment records are specific enough.
• Whether plaintiffs tie particular Medicare claims to product-related events.
• Whether reimbursement totals are supported by documentation and admissible proof.

3) Does the statute permit the claimed reimbursement methodology?

Disputes often turn on whether MSP allows reimbursement for all associated costs or only certain categories, and how plaintiffs calculate interest, penalties, or attorney’s fees.

What patent, Orange Book, or Paragraph IV issues exist in 3:18-cv-14414?

None are identifiable from the docket caption alone.
The named case is framed as an MSP recovery action, not as a Hatch-Waxman (ANDA/Orange Book) Paragraph IV infringement suit. Without the operative complaint text and docket entries, it is not possible to attribute any filing to patent assertions, listing disputes, or settlement agreements that would typically involve Orange Book listings or ANDA litigation.

Accordingly:

• This docket should be treated as an MSP statutory reimbursement matter unless the record shows otherwise.
• Any overlap with drug patents would be indirect, via product identification and the underlying medical events, not via a patent infringement claim.

How does this case compare with other MSP Recovery v. Pharma actions?

Common points across MSP Recovery pharma suits:

• Plaintiffs seek reimbursement of conditional Medicare payments tied to drug-related medical events.
• Plaintiffs rely on Medicare claims and CMS payment histories.
• Defendants argue that MSP does not extend to manufacturers as primary payers and that causation and evidentiary linkage are not met.

Typical defense outcomes in the MSP Recovery ecosystem (high-level):

• Courts may require strict proof of conditional payment amounts and proper notice.
• Many cases resolve through motions practice (pleading sufficiency, statutory scope) or through settlement following discovery on payment and linkage.

Because the question is a litigation summary “for” this specific docket, a reliable, docket-specific resolution map (e.g., dismissal, summary judgment, settlement) requires actual docket outcomes and orders, which are not present in the provided prompt.

What procedural timeline matters for MSP Recovery suits in this court?

In this litigation class, the most decision-relevant phases usually include:

1. Motion to dismiss

   • Challenges to whether MSP theory covers manufacturers.
   • Challenges to plausibility and sufficiency of pleading.

2. Discovery

   • Medicare payment records and causation evidence.
   • Notice and demand documentation.

3. Class or aggregate damages handling

   • Many MSP cases target large payment sets; courts often scrutinize whether aggregated damages are appropriate and supported.

4. Summary judgment

   • Causation and proof issues are frequently narrowed.

5. Settlement

   • Common where payment linkage and statutory exposure produce a commercial path to resolution.

For this specific docket, the exact dates of the motions and orders cannot be produced from the prompt alone.

What is the commercial and regulatory exposure for Pfizer if MSP liability is established?

If liability were sustained in an MSP Recovery case, exposure typically includes:

• Conditional payment reimbursement: the principal economic component, driven by the conditional payments identified.
• Interest: often computed from demand or a statutory date.
• Attorney’s fees and costs: depends on statutory entitlement and the court’s rulings.
• Downstream litigation leverage: losses can strengthen other MSP Recovery suits against related product lines or brand portfolios.

In pharma, even when MSP recoveries do not directly implicate regulatory approval, they can:

• Change settlement posture in other MSP actions.
• Affect vendor and compliance processes around medical coding and documentation.
• Create reputational and financial pressure across manufacturer product catalogs implicated in Medicare-payment link allegations.

What settlement terms are known for this docket?

No settlement agreement terms are contained in the prompt. A docket-specific settlement summary requires the filing or order text (settlement notice, stipulation, or judgment).

Key Takeaways

• MSP Recovery Claims, Series LLC v. Pfizer Inc. (3:18-cv-14414) is a Medicare Secondary Payer reimbursement action, not a Hatch-Waxman patent dispute based on the information provided in the prompt.
• The principal litigation issues in this category center on whether Medicare’s conditional payments are properly attributable to a legally recognized primary payer event involving Pfizer and on whether the plaintiff can tie specific Medicare payments to Pfizer-linked events with adequate proof and notice.
• Patent strength, Orange Book status, and Paragraph IV defenses are not inherently part of the case unless the operative complaint or docket orders show patent-related theories, which are not indicated in the prompt.

FAQs

1. Do MSP Recovery suits against pharma manufacturers require identifying an “underlying liability” scenario?
2. How do courts in MSP cases evaluate causation between drug use and Medicare conditional payments?
3. What role does notice and demand play in MSP Recovery reimbursement claims?
4. Are pharma MSP cases generally dismissed at the pleading stage, or do they proceed to discovery?
5. Does an MSP recovery claim create any collateral estoppel effect in separate drug litigation involving the same events?

References

1. MSP Recovery Claims, Series LLC v. Pfizer Inc., No. 3:18-cv-14414 (W.D. Pa. 2018) (case caption).
2. 42 U.S.C. § 1395y(b)(2)(B)(iii) (Medicare Secondary Payer reimbursement provisions).